IP Library Granted Patent US 10,668,013
Granted Patent B2
US 10,668,013 · App. 15/639,047 · Granted Jun 2, 2020

Chewable gelled emulsions

Inventors: Tore Seternes (Oslo, NO); Kurt Ingar Draget (Oslo, NO); Ingvild Johanne Haug (Oslo, NO)
Assignee: VITUX GROUP AS
A61K9/0056A61J1/035A61K9/107A61K31/00A61K31/192A61K31/51A61K31/519A61K31/525A61K31/59A61K31/675A61K31/714A61K31/7135A61K33/10A61K45/06A61K47/10A61K47/14A61K47/20A61K47/22A61K47/26A61K47/36A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,013
App. No.
15/639,047
Granted
Jun 2, 2020
Kind
B2
Abstract

An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.

Claims (9)

1. An oral pharmaceutical composition in uncoated dose unit form comprising a physiologically tolerable calcium compound within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, wherein the calcium compound is dispersed in one or both of the oil and aqueous phases of the emulsion, and wherein the calcium content per dose unit is at least 125 mg Ca, and further wherein the aqueous phase comprises a gelling agent which is a physiologically tolerable polysaccharide and which is present at a concentration of 0.2 to 5% wt. in the aqueous phase, and the weight of the dose unit is 1000 mg to 5000 mg.

2. The composition as claimed in claim 1 , containing particulate calcium carbonate.

3. The composition as claimed in claim 1 , further containing xylitol.

4. The composition as claimed in claim 1 , consisting of said gelled emulsion.

5. A pharmaceutical package comprising a composition as claimed in claim 1 , wherein said composition is foil-encased.

6. The package as claimed in claim 5 , in the form of a blister pack.

7. The composition as claimed in claim 1 , wherein the physiologically tolerable polysaccharide is a carrageenan, an alginate, an agar, a chitosan, a pectin, a gellan or a scleroglucan.

8. The composition as claimed in claim 1 , wherein the dose unit has a compression breaking strength of greater than 500 g/cm 2 .

9. The composition as claimed in claim 1 , wherein the gelled oil-in-water emulsion may be compressed at least substantially reversibly by at least 10% upon application of a force-deformation gradient of 0.1 mm/s at 21° C., 50% relative humidity and atmospheric pressure.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2017
From: SETERNES, TORE; DRAGET, KURT INGAR; HAUG, INGVILD JOHANNE
To: AYANDA AS
Reel/Frame 044395/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2017
From: AYANDA AS
To: PROBIO ASA
Reel/Frame 044396/0055 →
CHANGE OF NAME Recorded Nov 8, 2017
From: PROBIO ASA
To: AYANDA GROUP AS
Reel/Frame 044396/0242 →
ADDRESS CHANGE Recorded Nov 8, 2017
From: AYANDA GROUP AS
To: AYANDA GROUP AS
Reel/Frame 044396/0406 →
ADDRESS CHANGE Recorded Nov 8, 2017
From: AYANDA GROUP AS
To: AYANDA GROUP AS
Reel/Frame 044396/0657 →
CHANGE OF NAME Recorded Nov 8, 2017
From: AYANDA GROUP AS
To: VITUX GROUP AS
Reel/Frame 044711/0019 →
Priority Claims (1)
GB 0818473.1 · Oct 8, 2009 · national
Continuity (3)
Continuation 14515297 · Oct 15, 2014
Division 13123233
Related Publication 20170296467A1 · Oct 19, 2017